MSFT 414.2 2.0901% AAPL 220.11 -0.3621% NVDA 108.1 1.5309% GOOGL 148.66 -0.0336% GOOG 150.01 0.3143% AMZN 179.55 2.366% META 504.79 0.0% AVGO 148.21 5.2478% TSLA 226.17 4.5776% TSM 162.43 -0.215% LLY 901.25 -0.7729% V 285.34 -0.0945% JPM 205.56 -5.1889% UNH 599.03 0.8298% NVO 129.78 -1.6147% WMT 78.81 1.9007% LVMUY 135.45 -0.7401% XOM 110.82 -3.6432% LVMHF 676.0 -1.0402% MA 488.02 0.1909%
Last update at 2024-09-13T01:00:00Z
Ansell And 2 Other ASX Stocks That May Be Undervalued
Sun 08 Sep 24, 07:05 PMAnsell's (ASX:ANN) Soft Earnings Are Actually Better Than They Appear
Tue 27 Aug 24, 11:17 PM3 ASX Stocks Estimated To Be Trading At Up To 49.1% Discount
Thu 22 Aug 24, 07:04 PMAnsell Full Year 2024 Earnings: EPS Misses Expectations
Wed 21 Aug 24, 09:11 PMAnsell (ASX:ANN) May Have Issues Allocating Its Capital
Tue 20 Aug 24, 09:10 PMPRESS DIGEST- Wall Street Journal - April 8
Mon 08 Apr 24, 05:38 AMUPDATE 1-Ansell to buy Kimberley-Clark's personal protective equipment unit for $640 mln
Mon 08 Apr 24, 12:05 AM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 189.60M | 208.40M | 318.10M | 202.30M | 143.70M |
| Minority interest | -1.60000M | -1.10000M | 13.40M | 11.90M | 12.00M |
| Net income | 148.30M | 158.70M | 246.70M | 158.70M | 111.70M |
| Selling general administrative | 406.20M | 429.20M | 480.10M | 413.00M | 381.20M |
| Selling and marketing expenses | 406.20M | 429.20M | 480.10M | 413.00M | 381.20M |
| Gross profit | 616.70M | 665.80M | 810.00M | 632.70M | 584.00M |
| Reconciled depreciation | 68.00M | 65.30M | 64.10M | 55.59M | 54.55M |
| Ebit | 207.20M | 226.60M | 353.46M | 223.10M | 210.60M |
| Ebitda | 275.20M | 291.90M | 401.60M | 261.30M | 248.80M |
| Depreciation and amortization | 68.00M | 65.30M | 48.14M | 38.20M | 38.20M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 316.04M | 367.31M | 439.95M | 314.00M | 210.60M |
| Other operating expenses | 942.13M | 1223.75M | 989.26M | 814.48M | 1334.40M |
| Interest expense | 17.60M | 18.20M | 19.40M | 20.80M | 21.40M |
| Tax provision | 39.70M | 48.60M | 69.80M | 42.20M | 30.60M |
| Interest income | 17.70M | 24.50M | 1.20M | 14.50M | 11.10M |
| Net interest income | -19.40000M | -19.70000M | -18.20000M | -30.30745M | -19.39256M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 39.70M | 48.60M | 69.80M | 42.20M | 30.60M |
| Total revenue | 1655.10M | 1952.10M | 2026.90M | 1613.70M | 1499.00M |
| Total operating expenses | 474.20M | 494.50M | 544.20M | 451.20M | 419.40M |
| Cost of revenue | 1038.40M | 1286.30M | 1216.90M | 981.00M | 915.00M |
| Total other income expense net | -1.50000M | -8.50000M | 8.10M | -25.21260M | -66.90000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 149.90M | 159.80M | 248.30M | 233.28M | 161.27M |
| Net income applicable to common shares | 148.30M | 158.70M | 246.70M | 158.70M | 111.70M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 3242.60M | 2530.60M | 2506.20M | 2737.70M | 2448.60M |
| Intangible assets | 212.50M | 214.40M | 1049.40M | 225.70M | 231.20M |
| Earning assets | - | - | - | - | - |
| Other current assets | 37.40M | 31.10M | 38.10M | 37.40M | 25.10M |
| Total liab | 1332.40M | 915.20M | 949.60M | 1173.10M | 1045.20M |
| Total stockholder equity | 1894.90M | 1600.90M | 1542.90M | 1551.20M | 1391.50M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 120.40M | 367.69M | 185.83M | 256.72M | 272.85M |
| Common stock | 1028.20M | 750.70M | 743.80M | 769.00M | 806.00M |
| Capital stock | 1028.20M | 750.70M | 743.80M | 769.00M | 806.00M |
| Retained earnings | 1059.80M | 1026.60M | 942.00M | 866.80M | 705.70M |
| Other liab | - | 123.60M | 121.70M | 128.50M | 127.60M |
| Good will | 842.30M | 845.30M | 834.40M | 851.40M | 834.70M |
| Other assets | - | 114.10M | 95.80M | 114.70M | 101.00M |
| Cash | 912.30M | 159.40M | 206.20M | 240.20M | 408.90M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 423.40M | 414.60M | 360.30M | 549.90M | 408.40M |
| Current deferred revenue | - | -289.89286M | -120.02972M | -85.01800M | -152.84670M |
| Net debt | -55.10000M | 334.90M | 279.60M | 275.30M | 168.60M |
| Short term debt | 77.50M | 117.30M | 18.20M | 20.80M | 68.30M |
| Short long term debt | 59.70M | 100.00M | - | - | 72.85M |
| Short long term debt total | 857.20M | 494.30M | 485.80M | 515.50M | 577.50M |
| Other stockholder equity | - | -2668.43822M | -2441.71272M | -2181.50288M | -2179.44090M |
| Property plant equipment | - | 436.80M | 356.60M | 356.00M | 307.00M |
| Total current assets | 1623.90M | 912.00M | 984.50M | 1166.90M | 961.00M |
| Long term investments | 5.60M | 6.50M | 18.00M | 21.90M | 17.34M |
| Net tangible assets | - | 541.20M | 493.50M | 474.10M | 325.60M |
| Short term investments | - | 11.82M | 10.82M | 8.77M | 7.95M |
| Net receivables | 211.90M | 191.20M | 201.70M | 274.20M | 181.20M |
| Long term debt | 706.60M | 307.00M | 426.30M | 451.70M | 469.90M |
| Inventory | 457.90M | 526.10M | 521.30M | 611.20M | 340.10M |
| Accounts payable | 225.50M | 219.50M | 276.30M | 357.40M | 220.10M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -193.10000M | -176.40000M | -142.90000M | -84.60000M | -120.20000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 1174.41M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 42.60M | 42.00M | 32.60M | 32.70M | 34.30M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1618.70M | 1618.60M | 1521.70M | 1570.80M | 1487.60M |
| Capital lease obligations | 90.90M | 87.30M | 59.50M | 63.80M | 83.93M |
| Long term debt total | - | 377.00M | 467.60M | 494.70M | 509.20M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -75.50000M | -5.10000M | -1.70000M | -11.90000M | -11.90000M |
| Change to liabilities | -78.90000M | -94.70000M | 124.20M | 36.60M | 5.00M |
| Total cashflows from investing activities | -75.50000M | -71.20000M | -84.70000M | -74.80000M | -123.70000M |
| Net borrowings | -59.50000M | -17.10000M | -112.10000M | -37.90000M | -37.90000M |
| Total cash from financing activities | -149.20000M | -176.70000M | -267.50000M | -198.30000M | -253.40000M |
| Change to operating activities | 0.70M | -48.90000M | 16.10M | 6.80M | 4.40M |
| Net income | 222.66M | 229.86M | 329.00M | 226.91M | 111.70M |
| Change in cash | -46.80000M | -34.00000M | -168.70000M | 11.40M | -192.30000M |
| Begin period cash flow | 206.20M | 240.20M | 408.90M | 397.50M | 589.80M |
| End period cash flow | 159.40M | 206.20M | 240.20M | 408.90M | 397.50M |
| Total cash from operating activities | 271.00M | 321.54M | 230.45M | 415.43M | 188.90M |
| Issuance of capital stock | 0.30M | 103.20M | - | - | - |
| Depreciation | 96.99M | 87.19M | 76.55M | 73.46M | 38.20M |
| Other cashflows from investing activities | -8.30000M | -3.70000M | -2.00000M | -10.00000M | -4.70000M |
| Dividends paid | 62.90M | 86.80M | 77.30M | 61.80M | 60.20M |
| Change to inventory | 13.21M | 98.35M | -347.40280M | -20.28600M | 2.40M |
| Change to account receivables | 22.22M | 85.60M | -107.88824M | 17.53M | 3.50M |
| Sale purchase of stock | -8.00000M | -48.50000M | -58.00000M | -67.90000M | -181.10000M |
| Other cashflows from financing activities | -19.20000M | -45.80000M | -20.80000M | -198.65790M | -12.10000M |
| Change to netincome | 15.10M | 32.90M | 46.70M | 29.50M | 31.60M |
| Capital expenditures | 67.30M | 72.60M | 82.70M | 64.80M | 48.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 35.43M | 183.95M | -455.29104M | -2.75310M | - |
| Stock based compensation | -8.25770M | -3.76584M | 40.14M | 14.92M | - |
| Other non cash items | -48.64536M | 4.49M | -175.10168M | 115.05M | -149.90000M |
| Free cash flow | 203.70M | 248.94M | 147.75M | 350.63M | 140.90M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ANN Ansell Ltd |
0.47 1.56% | 30.60 | 33.82 | 17.01 | 2.71 | 1.53 | 1.76 | 14.08 |
| RMD Resmed Inc DRC |
-0.38 1.01% | 37.22 | 36.06 | 28.17 | 11.87 | 7.57 | 8.07 | 24.75 |
| FPH Fisher & Paykel Healthcare Corporation Limited |
-0.06 0.17% | 35.60 | 168.95 | 63.29 | 11.89 | 12.51 | 12.53 | 59.85 |
| NAN Nanosonics Ltd |
-0.01 0.28% | 3.53 | 88.75 | 120.48 | 6.33 | 6.02 | 5.69 | 44.96 |
| TRJ Trajan Group Holdings Ltd |
- -% | 1.22 | - | 175.44 | 1.18 | 1.82 | 1.50 | 21.80 |
Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables for hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and life sciences and pharmaceutical companies. The Industrial segment manufactures and markets hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, utilities, logistics, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.
678 Victoria Street, Richmond, VIC, Australia, 3121
| Name | Title | Year Born |
|---|---|---|
| Mr. Neil I. Salmon ACMA, BA | MD, CEO & Director | 1969 |
| Mr. Zubair Javeed | Chief Financial Officer | NA |
| Mr. Darryl Nazareth | Pres of Healthcare GBU | NA |
| Mr. Rikard Fröberg MA, MS | Pres of the Industrial Global Bus. Unit (IGBU) | NA |
| Mr. John Marsden | Sr. VP of Global Operations & Global Supply Chain | NA |
| Ms. Deanna Johnston | Sr. VP & Global Chief Information Officer | NA |
| Michael Evans | Director of Corp. Devel. & Investor Relation | NA |
| Mr. Michael Gilleece | Sr. VP & Corp. Gen. Counsel | NA |
| Ms. Amanda Manzoni | Chief HR Officer | NA |
| Mr. Francois Le Jeune BS, MBA, MS | Chief Commercial Officer of EMEA, APAC & Guardian Admin. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...